Simbrinza (Brinzolamide/Brimonidine Tart) Patent Expiration, LOE Window & CMS Spending

Simbrinza (Brinzolamide/Brimonidine Tart) by Novartis: FDA Orange Book LOE 2030-10-30, 0 AB generics, $83.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN204251 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2030-10-30
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$83.5M
2024 Medicare Part D Spend$78.9M
2024 Medicaid Spend$4.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.